Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Inclusion Criteria:

- Subject was randomized into protocol 20120262 and has completed the week 26 visit

Exclusion Criteria:

- Subject experienced a serious adverse event (SAE) or an adverse event (AE) in the
20120262 study that could cause extension treatment to be detrimental

- Subject has completed study 20120262 but cannot be dosed within 4 weeks of the week
26 visit of study 20120262

- Current infection requiring the use of oral or intravenous antibiotics

Other Inclusion/Exclusion criteria may apply